{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"Defined by either morphological or cytogenetic evidence of acute leukemia consistent with pre-transplant features, or radiologic evidence of lymphoma progression. When in doubt, the diagnosis of recurrent or progressive lymphoma should be documented by tissue biopsy.","groups":[{"description":"Conditioning: Fludarabine IV over 30-60 minutes daily on days -6 through -2 and cyclophosphamide IV over 1-2 hours on days -6, -5, and 3-4. Patients undergo total-body irradiation on day -1.\n\nCell product: Patients undergo donor peripheral blood stem cell transplant on day 0.\n\nGVHD Prophylaxis: Patients then receive tacrolimus IV once daily or PO BID on days 5-180 (may be continued if active GvHD is present), mycophenolate mofetil IV or PO TID on days 5-35 (may be continued if GvHD present), and filgrastim IV beginning on day 5 until the ANC is \\>= 1,000/mm\\^3 for three consecutive days.","id":"OG000","title":"Treatment (Nonmyeloablative HCT, TBI)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 7 years","title":"Relapse of Malignancy After Transplantation","type":"PRIMARY","unitOfMeasure":"percent"}